Hormone Replacement Therapy and Psychiatric Medications in Transgender Individuals

Cardiovascular Risk Considerations

Transgender women on estrogen therapy have an increased risk of venous thromboembolism, ischemic stroke, and myocardial infarction 1
This cardiovascular risk persists despite changes in estradiol dosing and preparations over time 1
When prescribing psychiatric medications with known cardiovascular effects, careful risk assessment is essential 1

Hormone therapy is associated with improved mental health outcomes in transgender individuals, including decreased depression and anxiety 2, 3
Studies show a 20% decrease in depression after 1 year of hormone treatment in transgender men and women 3
Quality of life improvements are documented, with transgender women experiencing a 16% improvement in QOL scores after 1 year of treatment 3
No evidence indicates that HRT has adverse mental health outcomes 3

Baseline assessment before starting combined therapy should include complete blood count, liver function, lipid profile, glucose, and baseline hormone levels, as well as assessment of cardiovascular risk factors 1
Monitoring protocol includes initial follow-up at 3 months to check estradiol and testosterone levels, and regular monitoring every 3-6 months during the first year, then annually if stable 1

Transgender individuals with autism and other neurodevelopmental conditions may require additional consideration, as these conditions are more prevalent in this population 4

Discontinuing HRT due to psychiatric medication needs can significantly worsen gender dysphoria and mental health outcomes 4, 5

Hormone therapy is associated with a 20% decrease in depression in transgender women after 1 year of treatment 6
No evidence indicates that GAHT has adverse mental health outcomes, according to the American College of Physicians 6

Progesterone is prescribed for its anecdotal effect of increasing breast growth in transgender women, as noted by the Mayo Clinic 7, 8

Discontinuing or reducing GAHT components significantly worsens gender dysphoria and mental health, which is a far greater risk than potential progesterone-related mood effects, as reported by the American Medical Association 9
Transgender individuals have increased rates of anxiety, depression, bipolar disorder, obsessive-compulsive disorder, ADHD, and schizophrenia compared to cisgender populations, according to the American Psychiatric Association 9
Any psychiatric symptom worsening should prompt evaluation of psychosocial stressors, medication adherence, and adequacy of psychiatric treatment, rather than immediately attributing changes to the progesterone increase, as recommended by the American College of Physicians 6, 9